Yeast Infection Treatment Market: Analyzing Market Trends, Growth Projections, and Competitive Landscape in Women's Health Solutions

The yeast infection treatment market size has grown strongly in recent years. It will grow from $4.02 billion in 2023 to $4.33 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increased prevalence of yeast infections, growing awareness about fungal infections, aging population, rise in healthcare expenditure globally, and development and approval of new antifungal medications.

The yeast infection treatment market size is expected to see strong growth in the next few years. It will grow to $5.53 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing adoption of telemedicine for remote consultations, personalized medicine approaches for targeted treatment, emergence of combination therapies for enhanced efficacy, growing emphasis on natural and herbal remedies, and focus on microbiome-based therapies for infection management. Major trends in the forecast period include advancements in genomic research, development of compact and accurate diagnostic equipment, technological advancements in the field of yeast infection diagnosis and treatment, increasing investments in research and development, and strategic partnerships.

Market Overview -
Yeast infection treatment is a medication employed to address and resolve infections caused by the overgrowth of the Candida fungus, commonly known as a yeast infection. These infections, known as candidiasis or yeast infections, can occur in various parts of the body, including the mouth (oral thrush), genitals (vaginal yeast infection), skin, and other mucous. They are used to relieve the symptoms of a yeast infection.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=13958&type=smp

Autoimmune Disease Surge Fuels Growth In Yeast Infection Treatment Market
The rise in the prevalence of autoimmune disease is expected to propel the growth of the yeast infection treatment market going forward. Autoimmune disease is a condition where the immune system mistakenly attacks healthy cells, tissues, and organs, weakening bodily function and potentially becoming life-threatening. Yeast infection treatment are used in managing and preventing the complications of autoimmune disease by addressing recurrent yeast infections, which are linked to certain autoimmune syndromes, and by potentially modulating the immune response through the management of fungal infections in patients with autoimmune conditions. For instance, in March 2023, according to the National Institutes of Health, a US-based federal agency for conducting and supporting medical research, an estimated 8.4 million people globally were predicted to have type 1 diabetes (T1DM) in 2021, with 500,000 new cases reported in that year. Further, the estimated population with T1DM is expected to be between 13.5 and 17.4 million by 2040. Therefore, the rise in the prevalence of autoimmune diseases is driving the growth of the yeast infection treatment market.

Competitive Landscape -
Major companies operating in the yeast infection treatment market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, Thermo Fisher Scientific Inc., Abbott Laboratories, AstraZeneca PLC, Bayer AG, Astellas Pharma Inc., Torrent Pharmaceuticals, Catalent Inc., bioMérieux SA, Cipla, Bruker Corporation, Brundavan Laboratories Private Limited, Glenmark Pharmaceuticals Ltd, Zydus Lifesciences, Prestige Consumer Healthcare Inc., CordenPharma International, Synmedic Laboratories, Basilea Pharmaceutica AG, Jubilant Pharmova Limited, Curia Global Inc., Synexis LLC, Manus Aktteva Biopharma LLP

Increasing Focus On Introducing Innovative Oral Antifungal Solutions To Revolutionize Yeast Infection Treatment
Major companies operating in the yeast infection treatment market are focusing on introducing innovative solutions or medications, such as non-azole oral antifungals, to gain a competitive edge in the market. A non-azole oral antifungal is a medication taken by mouth that fights fungal infections but does not belong to the azole class of antifungals. For instance, in December 2022, SCYNEXIS, a US-based biotechnology company, announced approval from the United States Food and Drug Administration (FDA), a US-based federal agency, for the second indication for BREXAFEMME (ibrexafungerp tablets). This is an innovative non-azole oral antifungal, the first FDA-approved therapy used for both the treatment of vaginal yeast infection, also known as vulvovaginal candidiasis (VVC), and the reduction in the incidence of recurrent VVC. It offers a novel alternative with broad-spectrum activity, impacting the dynamics of the yeast infection treatment market and addressing limited options for patients with recurrent VVC. The recommended dosage of BREXAFEMME for the treatment of VVC is 300 mg (two 150 mg tablets), given one day at a time, about 12 hours apart, for a total of 600 mg (four 150 mg tablets) every day.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/yeast-infection-treatment-global-market-report

Key Segments -

The yeast infection treatment market covered in this report is segmented -

1) By Type: Powders, Creams Or Ointments, Tablets Or Capsules, Other Types
2) By Treatment: Medical Treatment, Surgery
3) By Indication: Genital Candidiasis, Invasive Candidiasis, Oropharyngeal Or Esophageal Candidiasis (Thrush), Other Indications
4) By Route Of Administration: Oral, Topical, IV (Intravenous) Or IM (Intramuscular), Other Routes Of Administration
5) By Application: Retail Pharmacies Or Drug Stores, Hospital Pharmacies, Specialty Stores, Online Sales, Other Applications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.